Kristen Hege
Director/Board Member at MERSANA THERAPEUTICS, INC.
Net worth: 41 231 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Mott | M | 58 |
Dartmouth College
| 17 years |
| Martin Huber | M | 64 | 4 years | |
| Adrian Rawcliffe | M | 52 | 9 years | |
| Lawrence Alleva | M | 74 | 9 years | |
| David Elkins | M | 55 | 6 years | |
| Helena Tayton-Martin | M | 57 | 16 years | |
| Elliot Norry | M | 61 | 9 years | |
| Anna Protopapas | F | 59 | 9 years | |
| Allene Diaz | F | 59 | 3 years | |
| Antoni Ribas | M | 58 | 5 years | |
| John Furey | M | 59 | 6 years | |
| Ali Behbahani | M | 48 | 10 years | |
| Alejandra Carvajal | F | 50 | 3 years | |
| Willard Dere | M | 70 | 6 years | |
| Harry K. Genant | M | 81 |
The University of California, San Francisco
| - |
| Jessica Chao | F | - |
The University of California, San Francisco
| 10 years |
| Andrew Hack | M | 50 | 7 years | |
| Margaret Henry | F | - | - | |
| Robert Williams | M | 75 |
The University of California, San Francisco
| 14 years |
| Joanna Brewer | M | 47 | 15 years | |
| Brian DeSchuytner | M | 46 | 5 years | |
| Tushar Misra | M | 64 | 3 years | |
| Eric Matthews | M | - | 5 years | |
| Danielle Schlosser | M | - |
The University of California, San Francisco
| 11 years |
| Saptarsi Haldar | M | - |
The University of California, San Francisco
| - |
| Philip E. Wolfson | M | 79 |
The University of California, San Francisco
| 38 years |
| Ashish Mandelia | M | 50 | 5 years | |
| John Lunger | M | 55 | 7 years | |
| Ann Li Lee | M | 63 | 6 years | |
| Chuck Miller | M | - | 4 years | |
| Risa Kagan | M | - |
The University of California, San Francisco
| - |
| Mohan Bala | M | 59 | 3 years | |
| Ramona Doyle | M | 65 |
The University of California, San Francisco
| 13 years |
| Phil Bassett | M | - | - | |
| Irene McGlynn | F | - |
The University of California, San Francisco
| - |
| Sharp Kerry | F | - | 9 years | |
| Sheng Ding | M | - |
The University of California, San Francisco
| - |
| Catherine Lynch Gilliss | M | 75 |
The University of California, San Francisco
| 7 years |
| Juli P. Miller | M | - | 8 years | |
| Garry Menzel | M | 59 | 1 years | |
| John Nicols | M | 60 |
California Life Sciences Association
 California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019. | 10 years |
| Andrew Allen | M | 57 | 1 years | |
| Harold Messmer | M | 78 |
The University of California, San Francisco
| - |
| Ivan M. Lieberburg | M | 74 |
The University of California, San Francisco
| 36 years |
| Pamela Palmer | M | 61 |
The University of California, San Francisco
| 28 years |
| Marc K. Hellerstein | M | 72 |
The University of California, San Francisco
| 37 years |
| Kenneth Hao | M | 55 |
The University of California, San Francisco
| - |
| Radha Iyengar | M | - | 12 years | |
| Robin Kate Kelley | M | - |
The University of California, San Francisco
| 15 years |
| Jack D. McCue | M | - |
The University of California, San Francisco
| - |
| David A. Larson | M | 83 |
The University of California, San Francisco
| 38 years |
| Matthew Jacobson | M | - |
The University of California, San Francisco
| 22 years |
| Andrew Wolff | M | 69 |
The University of California, San Francisco
| 38 years |
| Terence W. Friedlander | M | - |
The University of California, San Francisco
| 13 years |
| Daniel Schwartz | M | 68 |
The University of California, San Francisco
| - |
| Priti Hegde | M | 52 | 1 years | |
| Jeffrey Olgin | M | - |
The University of California, San Francisco
| - |
| Dana Lynch | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sol Barer | M | 76 | 25 years | |
| Jacqualyn Fouse | M | 62 | 7 years | |
| Robert Hugin | M | 69 | 19 years | |
| Jonathan Biller | M | 61 | 8 years | |
| Peter Kellogg | M | 67 | 5 years | |
| Timothy J. Smith | M | - | - | |
| Jason Barker | M | 54 | 1 years | |
| Maxwell L. Anderson | M | - |
Dartmouth College
| 8 years |
| Thomas Daniel | M | 70 | 10 years | |
| Scott Smith | M | 61 | 10 years | |
| Sharon Tetlow | F | 64 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 4 years |
| Carrie Cox | F | 66 | 10 years | |
| Sara Nayeem | M | 75 | 6 years | |
| Sara Radcliffe | F | - |
California Life Sciences Association
California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019. | 4 years |
| Sandy Mahatme | M | 59 | 6 years | |
| Jonathan Farrington Weed | M | - |
Dartmouth College
| 6 years |
| Wayne Foster | M | 55 | 7 years | |
| Julia Haller | M | 69 | - | |
| Natalie Sacks | M | 59 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.
The University of California, San Francisco
| 14 years |
| Thomas Perone | M | 59 | 12 years | |
| Melissa C. Paoloni | M | - | 4 years | |
| Erik Lium | M | 56 |
The University of California, San Francisco
| 3 years |
| S. Connelly | M | - |
The University of California, San Francisco
| 8 years |
| Jay Backstrom | M | 69 | 11 years | |
| Michael Friedman | M | 80 | 8 years | |
| Tristram E. Collins | M | 60 |
Dartmouth College
| 4 years |
| Gilla Kaplan | M | 76 | 20 years | |
| Perry Karsen | M | 69 | 3 years | |
| Rodman L. Drake | M | 80 | 8 years | |
| John J. Schembri | M | 62 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 3 years |
| Patricia Hemingway Hall | F | 71 | 1 years | |
| John Weiland | M | 68 | 1 years | |
| Richard Morgan | M | 79 | 29 years | |
| William Rastetter | M | 75 | 6 years | |
| Charles Sigal | M | 72 | 8 years | |
| Richard W. Barker | M | 75 | 7 years | |
| Bart Geer | M | - |
Dartmouth College
| 8 years |
| Patrick E. Flanigan | M | - | - | |
| Keith P. R. Quinton | M | - |
Dartmouth College
| 6 years |
| Elaine Jones | M | 69 | 3 years | |
| Mitchell Finer | M | 65 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 10 years |
| Craig Dudenhoeffer | M | - |
The University of California, San Francisco
| 16 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 84 | 84.00% |
| United Kingdom | 18 | 18.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Kristen Hege
- Personal Network
